Inclusion body myopathy 2 (MB2) is a rare hereditary disease belonging to the group of myopathies. It is a chronic condition characterized by progressive muscle weakness and loss of muscle mass caused by damage to myofibrils and impaired muscle metabolism. The main pathology in this case is inclusions, which are protein aggregates that can be detected by microscopic examination. Clinical and laboratory features of the disease vary, but the leading manifestations are muscle weakness, fatigue, and the possibility of developing myalgia. The disease is more common in women, especially at an older age, and can lead to disability, which emphasizes the importance of early diagnosis and therapy.
History of the disease and interesting historical facts
The history of inclusion body myopathies began its clear chronicle in the mid-20th century with the first descriptions of pathomorphological changes in muscle tissue. Soon, the scientific community turned its attention to group characteristics and various phenotypes that required further study. It is noteworthy that a significant part of the data on inclusion body myopathies was obtained thanks to anatomopathological studies carried out on muscle tissue samples obtained from patients with various clinical manifestations. An important moment in the history of MB2 was the isolation of specific proteins, such as transcription factors and small RNAs, which became the object of study in the context of the pathogenesis of the disease. This contributed to the understanding of the molecular mechanisms of myopathy development and the proposal of new directions for research and clinical work.
Epidemiology (statistics of disease occurrence)
According to epidemiological studies, the prevalence of inclusion body myopathies is approximately 1 case per 100,000 population, with cases occurring more frequently in certain ethnic groups. An important aspect is the fact that the disease may not be diagnosed in the early stages, which complicates the calculation of the real incidence. There are differences in statistics in different countries, which may be due to diagnostic problems and differences in access to modern molecular genetic research methods. It should also be noted that the age of onset of the disease can vary greatly, which in turn complicates the understanding of the true epidemiological situation.
Genetic predisposition to the disease (involved genes and mutations)
Genetic predisposition to inclusion body myopathy 2 is associated with mutations in a number of genes, the most significant of which are genes encoding proteins responsible for the metabolism and structure of myofibrils. In particular, mutations in the GNE, VCP and UBQLN2 genes are distinguished, which cause specific molecular defects. Studies show that carriage of these mutations does not always lead to the disease, which indicates a complex multifactorial nature of pathogenesis and affects the possibility of developing genetic screening for predisposed population groups. Currently, active research is being conducted to identify new mutations and their role in the pathogenesis of the disease.
Risk factors for the development of this disease (physical and chemical risk factors, other possible ones associated with this disease)
Risk factors that contribute to the development of inclusion body myopathy can be both genetic and external. Genetic factors, as already mentioned, include specific mutations in genes associated with myofibrillar degeneration. External risk factors include:
- Exposure to chemical toxins, particularly heavy metals and solvents, which can have a negative impact on muscle cells;
- Physical stress and injuries, which can contribute to the development of pathology against the background of already existing predisposing factors;
- A number of infectious diseases that can affect metabolic processes in muscle tissue;
- The presence of concomitant diseases such as diabetes or thyroid disorders.
Diagnosis of this disease
Diagnosis of inclusion body myopathy involves a number of methods, from clinical examination to specialized laboratory and instrumental studies. The main symptoms of the disease include progressive muscle weakness, as well as possible dysfunction of the shoulder girdle and hips. Laboratory studies usually include a blood test for creatine kinase levels, which may be elevated. Radiological examinations, such as MRI, may reveal atrophic changes in muscle tissue. In addition, muscle biopsy with subsequent morphological and immunohistochemical analysis is key to confirming the diagnosis. The differential diagnostic process should take into account possible other myopathies, neuromuscular disorders, and genetically determined diseases.
Treatment
Treatment of inclusion body myopathy involves a systemic approach aimed at minimizing the manifestations of the disease and slowing its progression. This may include both general treatment and specific pharmacological interventions. Physiotherapy procedures are prescribed first, which improve muscle function and reduce the risk of atrophy. In some cases, anti-inflammatory drugs are prescribed to control inflammatory processes. Pharmacological treatment may include corticosteroids, but their use requires caution due to possible side effects. Surgical treatment may be necessary in case of contractions or other mechanical limitations that arise due to the disease. Newer therapies, such as gene therapy, which are under active research, are also relevant.
List of medications used to treat this disease
- Corticosteroids (prednisolone, methylprednisolone);
- Anti-inflammatory drugs (diclofenac, ibuprofen);
- Muscle relaxants (methocarbamol, baclofen);
- Drugs to improve microcirculation (pentoxifylline);
- New experimental drugs that are in clinical trials.
Disease monitoring
Monitoring of inclusion body myopathy involves regular examination of patients to assess the dynamics of the disease, its progression, and correction of treatment. Control stages include periodic laboratory tests, clinical examination, and monitoring of the patient's functional status. The prognosis depends on the time of initiation of therapy and the individual characteristics of the patient, but many patients suffer from severe complications associated with progressive muscle weakness, which can lead to a decrease in quality of life and loss of independence.
Age-related features of the disease
The course of inclusion body myopathy can vary significantly depending on the age group. In older patients, the disease usually has a more severe course, with a pronounced loss of muscle strength and functional capabilities. While in younger people, the disease may manifest itself with less pronounced symptoms and also be more easily corrected. The most pronounced symptoms are observed in older age, where the risk of developing concomitant diseases that worsen the general condition also increases.
Questions and Answers
- What is the cause of inclusion body myopathy 2? The main reason is mutations in the genes responsible for the function and structure of myofibrils, which leads to their damage and the formation of pathological inclusions.
- Is it possible to prevent the development of the disease? Given its genetic predisposition, it is impossible to completely prevent the disease, but early diagnosis and timely treatment can slow down its progression.
- How is inclusion body myopathy diagnosed? Diagnosis includes clinical evaluation, laboratory tests (blood tests), muscle biopsy and immunohistochemical methods.
- Which treatment is most effective? The most effective treatment is a comprehensive approach that includes physical therapy, medication and, if necessary, surgery.
- What are the possible complications of inclusion body myopathy? Potential complications include progressive muscle weakness, contractures, and the risk of falls and related injuries.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends the following to maintain the quality of life of patients with inclusion body myopathy: “It is important not to miss the early signs and to contact specialists at the first symptoms of the disease. Regular physical therapy will help maintain muscle tone. It is also necessary to strictly monitor the level of vitamins and minerals in the body, as they can significantly affect overall health. To monitor the disease, undergo regular examinations and maintain contact with your doctor. Monitor the physical activity regimen and psycho-emotional state, this plays a key role in the exacerbation or improvement of the course of myopathy.”
